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A protocol utilizing both leuprolide acetate (LA) and
norethindrone acetate (NETA) in subjects undergoing
ovarian suppression prior to follicle aspiration proved more
effective than LA alone in reducing the incidence of ovarian
cyst formation without affecting clinical outcome. Patients
(n = 105) undergoing ovarian stimulation followed by
follicle aspiration and in-vitro fertilization (TVF) were
prospectively randomized and studied. Study measures
included ovarian suppression days, days of human meno-
pausal gonadotrophin (HMG) stimulation, serum oestradiol
concentrations, number of cycles developing de novo cysts
(>15 mm), number of induced flare responses (day 8
oestradiol 3*50 pg/ml), number of office visits, total dose
exogenous gonadotrophins, number oocytes retrieved, and
clinical pregnancy and delivery rates per retrieval. Patients
undergoing FVF received either LA alone (n = 58; controls)
or LA and NETA (n = 47; study group) for the first 8
days of their cycle. Results comparing NETA/LA versus
LA demonstrated: serum oestradiol 20.7 ± 3.9 versus 573
± 9.4 pg/ml respectively on day 8 of ovarian suppression
(P < 0.01); 8.6 ± 2.74 days required for ovarian suppression
versus 123 ± 6.09 days (P < 0.01); and only three
individuals (6.4%) using NETA/LA developed ovarian cysts
>15 mm compared to 15 (25.9%) controls (P < 0.01). No
differences were observed for days of stimulation, peak
oestradiol attained, total dosage of exogenous gonado-
trophins, or number of aspirated oocytes. Neither were
there differences in the clinical pregnancy (26.8 versus
22.6%) nor in delivery rates (19.5 versus 20.8%). We
conclude that the addition of NETA to LA enhances ovarian
suppression and lessens ovarian cyst formation, thereby
significantly decreasing the overall cost per cycle.
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Introduction
The use of the gonadotrophin-releasing hormone agonists
(GnRHa) has become commonplace in the treatment of repro-
ductive disorders. GnRHa are useful adjuncts in combination
with menotrophins for ovarian hyperstimulation. GnRHa
prevents premature luteinization and premature luteinizing
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hormone (LH) surges. Suppressing the pituitary with GnRHa
prior to ovarian stimulation results in a greater number of
oocytes recovered by enlarging the recruitment pool (Porter
et al, 1984; Neveu et al, 1987), thus increasing the number
of embryos while improving embryo quality in patients under-
going in-vitro fertilization (TVF).
However, down-regulation with GnRHa requires 1-3 weeks
(Yen, 1983) and is associated with an initial agonistic (stimula-
tory) phase that may result in ovarian follicular cyst formation
(Sampaio et al, 1991). Accordingly, studies have been carried
out utilizing pure GnRH antagonists to prevent these adverse
occurrences (Cassidenti et al, 1991). Antagonists induce
immediate decreases in circulating gonadotrophin concentra-
tions and do not exhibit agonistic effects (Ditkoff et al,
1991). Unfortunately GnRH antagonists are difficult to obtain,
expensive, and have potential harmful side-effects related to
histamine release. Furthermore, their current use and availabil-
ity is limited.
Progestins and oral contraceptives have also been used
prior to ovarian stimulation (Gerli et al, 1989; Kemeter and
Feichtinger, 1989; Hughes et al, 1992; Franco et al, 1995;
Gonzalez et al, 1995).
Reports demonstrate that oral contraceptive use prior to
ovarian stimulation minimizes the risk of hyperstimulation in
high risk patients (Neal et al, 1993). However, these protocols
typically require patients to take medications for many days
prior to starting ovarian stimulation. The use of these medica-
tions is based upon the knowledge that progestins directly
inhibit GnRHa stimulation (Anderson et al, 1990; Poindexter
et al, 1993) and have a major influence on the pattern of
hypothalamic GnRH secretion by centrally suppressing the
release of gonadotrophins (Hemrika et al., 1993).
The purpose of this study was to determine whether norethin-
drone acetate (NETA) used in combination with leuprolide
acetate (NETA+LA), induces down-regulation as efficiently
or more so than LA alone when administered during the early
follicular phase. Furthermore, we wished to determine if
enhanced ovarian suppression lessens the flare effect commonly
seen with GnRHa therapy as manifested by the formation of
ovarian cysts.
We chose to study this protocol during the early follicular
phase because it is common practice in the USA to start
GnRHa at this time during the menstrual cycle, since ovulatory
patients with tuba! patency are not then concerned about
pregnancy while taking LA.
Materials and methods
Patients
The study was approved by the Institutional Review Board of






















enrolled at the time of their initial attempt at ovarian stimulation and
follicle aspiration for IVF. Patients were randomly assigned by tossing
a coin to one of two groups. Indications for IVF included male
factor, tubal obstruction, endometriosis, pelvic or uterine factor, and
idiopathic infertility. All patients had day 3 follicle stimulating
hormone (FSH) values <15 mlU/ml. The various infertility diagnoses
were distributed equally between the control and study groups. Group
I comprised 58 women (mean age ± SD, 35.8 ± 4.57 years; range
23—43 years) who served as controls and underwent the standard
protocol. Group I patients injected LA (1 mg s.c. daily) during the
first 8 days of their menstrual cycle. Group II comprised 47 women
(mean age 36.7 ± 4.80 years; range 28-44 years) who served as
study patients and underwent daily injections of LA (1 mg s.c.) and
oral NETA (10 mg in divided doses kindly supplied as Aygestin from
Wyeth-Ayerst, Philadelphia, USA) for the first 8 days of their cycle.
Ovarian suppression protocol
All subjects demonstrated normal pelvic ultrasound results immedi-
ately prior to ovulation induction. Patients were seen on the morning
of day 8 of LA+NETA for serum oestradiol and vaginal ultrasound.
Ovarian suppression was defined as an oestradiol level <30 pg/ml.
De-novo ovarian cysts were considered enlarged if & 15 mm maximum
diameter. Regardless of the presence of an ovarian cyst, if the serum
oestradiol level was ^ 3 0 pg/ml, ovarian stimulation was initiated. If
the serum oestradiol was >30 pg/ml, LA alone was continued and
the patient returned 1 week later (day 15) for further monitoring or
weekly thereafter until ovarian suppression (oestradiol <30 pg/ml)
was evident.
Ovarian stimulation phase
All subjects underwent an identical protocol for ovarian stimulation
consisting of 225 IU human menopausal gonadotrophins (HMG)
injected i.m. daily while injecting 1 mg of LA s.c. The initial visit
for monitoring the stimulation occurred after 4 days of HMG therapy.
If the serum oestradiol was <80 pg/ml, the dose of HMG was
increased to a maximum of 450 IU. If a patient had recruited two or
fewer follicles with a serum oestradiol of =£300 pg/ml, the cycle was
cancelled. Human chorionic gonadotrophin (HCG, 10 000 IU) was
administered i.m. when lead follicles reached 18 mm in diameter. In
general the serum oestradiol value was at least 150 pg/ml per mature
lead follicle. Oocyte retrieval was scheduled 34-36 h after HCG.
Trans vaginal embryo transfer occurred 48 h after retrieval. Quantitat-
ive measurements of P-HCG were performed on days 10 and 14
post-transfer. If positive (>2 mlU/ml) and rising, the measurement
was repeated 7 days later. Pregnancy viability was assessed by vaginal
ultrasound 28 days post-transfer.
Hormone assays
Blood was separated, and fresh sera analysed for oestradiol by a
highly specific direct radioimmunoassay (Diagnostic Products, Los
Angeles, CA, USA). The intra-assay and inter-assay coefficients
of variation were 5 and 6.2% respectively. Assay sensitivity was
10 pg/ml.
Statistical analyses
Data were expressed as mean ± SD, and were analysed by Levene's
test for equality of variances (independent t testing), Fisher's exact
test, and multiple regression analysis utilizing SPSS for MS Windows
6.0 as appropriate. Significance was defined as a P value <0.05.
Results
Table I compares the two groups of patients during ovarian
suppression. The day 8 oestradiol value for NETA+LA admin-
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Table I. Comparison of leuprolide acetate (LA) alone to LA +
norethindrone acetate (NETA) patients prior to ovarian stimulation
LA alone LA + NETA
Cycles
Days until suppression
Day 8 oestradiol (pg/ml)
(mean ± SD)
Cyst cycles (n) (%)
Rare cycles
(oestradiol >30 pg/ml) (n)
Total visits



















Values in parentheses are ranges.
U>x.<Uya]ues ^ ( j , same superscript are significantly different (/> < 0.05).
Table IL Comparison of ovarian













stimulation parameters and pregnancy rates

























HMG = human menopausal gonadotrophin.
istration was significantly less than LA used alone [20.7 ±
26.9 versus 57.3 ± 71.7 pg/ml (P < 0.05)]. Furthermore,
there was a significantly lower incidence of initial agonist
(flare) responses (three versus 23) and cyst formation (three
versus 15) (P < 0.05) for the combined treatment. Patients
using LA alone required more days to achieve ovarian suppres-
sion (12.3 ± 6.05 versus 8.6 ± 2.8) and more office visits
during the interval of down regulation [1.6 ± 0.86 versus 1.1
± 0.43 (P < 0.01)].
Table II depicts ovarian stimulation parameters and preg-
nancy rates between groups. There were no significant differ-
ences in cancellation rates, days of ovarian stimulation, peak
oestradiol value on the day of HCG administration, amount of
exogenous gonadotrophins used, or number of oocytes
retrieved. Furthermore, there were no differences in rates for
clinical pregnancy or ongoing delivery per retrieval.
A significant correlation existed between day 8 oestradiol
and the number of days required to achieve ovarian suppression
(r = 0.69, P < 0.05). Patients (n = 18) with ovarian cysts on
day 8 all had oestradiol values >30 pg/ml (mean ± SD 140
± 97.2 pg/ml). These 18 patients also required a longer period
of time for suppression (20.6 ± 0.26 days) compared to
patients (n = 87) without cysts (9.6 ± 0.09 days).




















Norethindrone acetate and ovarian stimulation
experienced by patients in either group related to the use of
their medication.
Cysts were relatively common when NETA was not used,
as demonstrated by 26% of control patients, but were present
in only 6% of study patients (P < 0.05).
Discussion
Our data reveal that the concomitant administration of LA
and NETA during the early follicular phase induces ovarian
suppression more efficiently than LA alone. Evidence
supporting this includes a reduced serum oestradiol on day 8
and a lower incidence of ovarian cyst formation. Study patients
did not experience adverse effects during ovarian stimulation
nor were pregnancy rates affected.
The close association between ovarian cyst formation and
elevated estradiol concentrations on day 8 suggests that these
cysts result from the initial agonist effect of LA. This was
inferred since patients with pre-existing cysts during baseline
scans were excluded from study. Also, patients with ovarian
cysts on day 8 had associated elevated oestradiol levels
and required a longer time to achieve full suppression. The
decreased incidence of ovarian cyst formation in the study
group is believed to be due to the known direct effect of
NETA on the hypothalamic-pituitary axis (Poindexter et al,
1993). NETA blocked the initial agonistic flare response from
LA in all but four study patients (8.5%). Three of these four
patients developed ovarian cysts and elevated oestradiol levels
(118 ± 139pg/ml).
The use of LA+NETA for down-regulation during the early
follicular phase may be more efficient than using LA alone.
Less LA is required, and office visits and overall cost are thus
minimized. The monitoring of ovarian stimulation is simplified
when ovarian cysts do not form, and protracted follow-up
necessitated by cyst formation is obviated.
Other studies have utilized progestins and oral contraceptives
in IVF protocols. Gerli et al. (1989) gave oral NETA, 10 mg
daily, starting between cycle days 2-4 of the previous cycle.
The NETA was used for 9-37 days and then discontinued.
Ovarian stimulation was then carried out with a combination
of LA and exogenous gonadotrophins until HCG was given.
Hughes et al. (1992) gave norethisterone 10 mg/day for 14
days, beginning on day 15 of the cycle which immediately
preceded the IVF cycle. On day 3 after cessation of pre-
treatment with norethisterone, a GnRHa was given. HMG was
prescribed 4-5 days later and subsequent doses were adjusted
according to serum oestradiol and ultrasound imaging. Franco
et al. (1995) used a protocol consisting of a low-dose contra-
ceptive (30 u.g ethinyloestradiol and 75 (J.g gestodene) from
day 1 of the menstrual cycle preceding the cycle of ovarian
stimulation and continued for 21-28 days. Ovarian stimulation
was started on day 5 after discontinuation of the pill with 100
mg/day clomiphene citrate.
Our study design did not enable us to evaluate the mechanism
of action of NETA nor the minimal time required for ovarian
suppression. Future studies should be carried out to address
these issues. We postulate that NETA prevents the initial
release of gonadotrophins from the pituitary. Anderson et aL
(1990) utilized norethindrone (NET) for cycle programming.
They assessed the effects of NET on gonadotrophin secretion,
its bio-availability to the ovary, and its effect on ovarian
steroidogenesis in vivo and in vitro. These authors concluded
that NET did not inhibit ovarian steroidogenesis but had direct
effects on the hypothalamic-pituitary axis.
In summary, NETA+LA administration during the early
follicular phase is useful for women undergoing ovarian
stimulation. The combination of NETA and GnRHa is more
efficient than GnRHa alone, since ovarian suppression occurs
earlier and the incidence of ovarian cyst formation decreases
significantly. Thus, the addition of NETA to LA decreases
costs. Patients may ultimately prefer this approach, since
suppression is more certain and the majority of patients will
not develop follicular cysts.
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